氯喹在孕期疟疾化学预防中的安全性。
Safety of chloroquine in chemosuppression of malaria during pregnancy.
作者信息
Wolfe M S, Cordero J F
出版信息
Br Med J (Clin Res Ed). 1985 May 18;290(6480):1466-7. doi: 10.1136/bmj.290.6480.1466.
A cohort of 169 births to women who were exposed throughout pregnancy to chloroquine 300 mg base once a week for chemosuppression of malaria was studied. The birth defects in this cohort were compared with those in a control group of 454 births to women who were not exposed to chloroquine, most of whom lived in non-malarious areas. The proportion of birth defects in the exposed group was not significantly different from that in the control group. This observation must be considered within the limitations of the study, which could detect only a strong teratogenic effect. It could not exclude risks lower than a 5.7-fold increase in the incidence of birth defects when chloroquine was used. Women using chloroquine during pregnancy for chemosuppression of malaria can be reassured that it is not a strong teratogen, but if it is to be used the risk of developing malaria should be balanced against the lack of data to determine whether it carries a low teratogenic risk.
对一组169名在孕期每周一次接受300毫克碱基氯喹进行疟疾化学预防的妇女所生婴儿进行了研究。将该队列中的出生缺陷情况与对照组的454名未接触氯喹的妇女所生婴儿进行了比较，对照组中的大多数妇女居住在非疟疾流行地区。暴露组的出生缺陷比例与对照组无显著差异。必须在该研究的局限性范围内看待这一观察结果，该研究只能检测到强烈的致畸作用。它无法排除使用氯喹时出生缺陷发生率增加低于5.7倍的风险。孕期使用氯喹进行疟疾化学预防的妇女可以放心，它不是一种强烈的致畸剂，但如果要使用，应权衡患疟疾的风险与缺乏数据以确定其是否存在低致畸风险之间的关系。
Zotero 插件